Physician profile
Andrew Woolf
NPI 1346632643
$3,364.84
in general payments reported to CMS, 2019-2025
26 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $187 · 2021: $303 · 2022: $927 · 2023: $951 · 2024: $467 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.69 | 2019-2024 | Skyrizi, Rinvoq, Mavyret |
| Olympus America INC. | $741.66 | 2022-2025 | Endoclot Phs, Olympus, Visiglide |
| Genzyme Corporation | $208.97 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.76 | 2021-2023 | Entyvio |
| Janssen Biotech, INC. | $183.61 | 2019-2024 | Tremfya, Simponi Aria, Stelara |
| Boston Scientific Corporation | $157.87 | 2021-2024 | Exalt Model D, Resolution 360 Clip |
| Conmed Corporation | $152.79 | 2023 | Conmed Biliary |
| Janssen Scientific Affairs, LLC | $131.39 | 2019-2020 | |
| Gilead Sciences, INC. | $119.70 | 2020 | |
| Medtronic, INC. | $103.69 | 2025 | Pillcam |
| Capsovision, INC. | $95.07 | 2025 | Capsocam Plus |
| Celgene Corporation | $85.52 | 2022-2023 | Zeposia |
| Lucid Diagnostics INC. | $72.52 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $70.90 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $59.23 | 2023-2024 | Ocaliva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $51.35 | 2023 | Sutab, Suflave |
| W. L. Gore & Associates, INC. | $24.62 | 2023 | Gore Synecor Biomaterial |
| E.R. Squibb & Sons, L.L.C. | $23.22 | 2022 | |
| Allergan, INC. | $18.25 | 2019 | |
| Shionogi INC | $18.16 | 2019 | |
| Pfizer INC. | $15.60 | 2023 | |
| Alnylam Pharmaceuticals INC. | $14.19 | 2024 | Amvuttra |
| Madrigal Pharmaceuticals | $13.24 | 2024 | Resmetirom |
| Ferring Pharmaceuticals INC. | $12.17 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.96 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Woolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.